Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rittenhouse, S.
Right arrow Articles by Coleman, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rittenhouse, S.
Right arrow Articles by Coleman, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 23
© 2000 The British Society for Antimicrobial Chemotherapy

In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens

Stephen Rittenhouse*, Lynn McCloskey, John Broskey, Nancy Niconovich, Charles Jakielaszek, James Poupard and Ken Coleman

SmithKline Beecham Pharmaceuticals, Upper Providence, PA, USA

This study investigated the in vitro potency of the novel quinolone agent gemifloxacin (SB-265805), in comparison with other quionolones, ß-lactams, macrolides and trimethoprim– sulphamethoxazole, against a panel of common respiratory pathogens. This panel comprised recent clinical isolates of Streptococcus pneumoniae (n = 347), Haemophilus influenzae (n = 256) and Moraxella catarrhalis (n = 184). Overall, the quinolones were highly active against H. influenzae and were the most potent agents against M. catarrhalis. Gemifloxacin was the most potent quinolone tested against all three species and was four- to 512-fold more potent against pneumococci than trovafloxacin, grepafloxacin, levofloxacin, ciprofloxacin, ofloxacin, gentamicin, cefuroxime, penicillin, ampicillin, clarithromycin, azithromycin or trimethoprim– sulphamethoxazole. Against 19 ofloxacin-intermediate and 52 ofloxacin-resistant strains of S. pneumoniae, gemifloxacin retained activity, and was the only agent tested with MICs of <=0.5 mg/L. The results of this study demonstrate the excellent in vitro antibacterial activity of gemifloxacin against pathogens commonly associated with respiratory tract infections and suggest that gemifloxacin has significant potential in the treatment of such infections, including those caused by pneumococci considered resistant to other quinolones.

* Correspondence address. Microbiology Research, SmithKline Beecham Pharmaceuticals, 1250 S. Collegeville Road, Collegeville, PA 19426-0989, USA. Tel: +1-610-917-6273; Fax: +1-610-917-4617; E-mail: Stephen_Rittenhouse{at}SBPHRD.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
E. Azoulay-Dupuis, J. P. Bedos, J. Mohler, P. Moine, C. Cherbuliez, G. Peytavin, B. Fantin, and T. Kohler
Activity of Gemifloxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model
Antimicrob. Agents Chemother., March 1, 2005; 49(3): 1046 - 1054.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
B. K Yoo, D. M Triller, C.-S. Yong, and T. P Lodise
Gemifloxacin: A New Fluoroquinolone Approved for Treatment of Respiratory Infections
Ann. Pharmacother., July 1, 2004; 38(7): 1226 - 1235.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.